김상위
#폐암#흉선종양#악성중피종#신경계암
|
학력
1992 .03 ~ 1994 .02울산대학교 의학 석사
1979 .03 ~ 1985 .02서울대학교 의학 학사
경력
2013 .03 ~ 현재서울아산병원 암센터 폐암센터 소장
1992 .03 ~ 1994 .02서울아산병원 전임의
1989 .05 ~ 1992 .02서울아산병원 레지던트
1985 .03 ~ 1986 .02서울대병원 인턴
1992 .03 ~ 1994 .02서울아산병원 전임의
1989 .05 ~ 1992 .02서울아산병원 레지던트
1985 .03 ~ 1986 .02서울대병원 인턴
논문
Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS.
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.
Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations.
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na?ve patients (pts) with EGFR mutant NSCLC.
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epid
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Bone metastasis in pulmonary sclerosing hemangioma
Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.
Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations.
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na?ve patients (pts) with EGFR mutant NSCLC.
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epid
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Bone metastasis in pulmonary sclerosing hemangioma
Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.
저서
암에 대한 모든 것 (가림건강신서 54)
보도자료
[의술인술]폐암 면역항암제, 교체 투여 땐 ‘급여 불가’…첫 선택 신중해야
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201711282134025&code=900303
MSD 면역항암제 ‘키트루다’ 폐암 2차 치료제로 사용 가능
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201605052113015&code=900303
[Health] 김상위 서울아산병원 종양내과 교수 "표적항암제 등장으로 4기 폐암환자도 생존기간 1년 이상 늘어나"
https://www.hankyung.com/news/article/2016032973231
국내 연구진 폐암 표적항암제 한계 극복, 새로운 내성기전 밝혀
http://news.kukinews.com/news/article.html?no=50228
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201711282134025&code=900303
MSD 면역항암제 ‘키트루다’ 폐암 2차 치료제로 사용 가능
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201605052113015&code=900303
[Health] 김상위 서울아산병원 종양내과 교수 "표적항암제 등장으로 4기 폐암환자도 생존기간 1년 이상 늘어나"
https://www.hankyung.com/news/article/2016032973231
국내 연구진 폐암 표적항암제 한계 극복, 새로운 내성기전 밝혀
http://news.kukinews.com/news/article.html?no=50228
포스팅
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
영상자료
영상자료 내용이 없습니다.
발표자료
Management of Airway Involvement of Esophageal Cancer Using Covered Retrievable Nitinol Stents
Palliative Treatment of Inoperable Malignant Tracheobronchial Obstruction: Temporary Stenting Combined with Radiation Therapy and/or Chemotherapy
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never smokers with adenocarcinoma of the lung and asymptomatic synchronous brain metastasis.
Assessments of the epidermal growth factor receptor mutations and amplification and their clinical implication in patients with lung adeno-carcinoma
Epidermal growth factor receptor (EGFR) and KRAS mutations in non-small cell lung cancer (nsclc) patients treated with gefitinib
The effect of NQO1 polymorphisms on prognosis of non-small cell lung cancer after postoperative radiation therapy
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial.
Application of serum proteomic patterns in diagnosis of lung disease using the aptamer-based biochps
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
Prospective Randomized Phase Ⅲ Trial of KROG 03-02 on the Induction Chemotherapy in the Concurrent Chemoradiotherapy for the Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
Palliative Treatment of Inoperable Malignant Tracheobronchial Obstruction: Temporary Stenting Combined with Radiation Therapy and/or Chemotherapy
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never smokers with adenocarcinoma of the lung and asymptomatic synchronous brain metastasis.
Assessments of the epidermal growth factor receptor mutations and amplification and their clinical implication in patients with lung adeno-carcinoma
Epidermal growth factor receptor (EGFR) and KRAS mutations in non-small cell lung cancer (nsclc) patients treated with gefitinib
The effect of NQO1 polymorphisms on prognosis of non-small cell lung cancer after postoperative radiation therapy
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial.
Application of serum proteomic patterns in diagnosis of lung disease using the aptamer-based biochps
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
Prospective Randomized Phase Ⅲ Trial of KROG 03-02 on the Induction Chemotherapy in the Concurrent Chemoradiotherapy for the Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung